The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis-Reference-Cited by-同舟云学术

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis

Published:2023-08-28 Issue:4 Volume:23 Page:331-338
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Vališ Martin,Achiron Anat,Hartung Hans Peter,Mareš Jan,Tichá Veronika,Štourač Pavel,Halusková Simona,Angelucci Francesco,Pavelek Zbyšek^ORCID

Funder

Charles University in Prague, Czech Republic

grant projects of the Ministry of Health of the Czech Republic

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40268-023-00434-6.pdf

Reference65 articles.

1. Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19:1–10.

2. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.

3. Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L. The immunology of multiple sclerosis. Nat Rev Immunol [Internet]. 2022. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35508809.

4. Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ, International Advisory Committee on Clinical Trials in MS. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology. 2020;94:1088–92.

5. Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Markers of secondary progression in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-11

2. Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series;Clinical Neurology and Neurosurgery;2024-10

3. Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities;Biomedicine & Pharmacotherapy;2024-08

4. Optical coherence retinal tomography as a prognostic biomarker of multiple sclerosis progression;Russian neurological journal;2024-07-23

5. Repurposing the multiple sclerosis drug Siponimod for osteoporosis treatment;European Journal of Pharmacology;2024-07